中国同辐(01763.HK)附属与北京师范大学签署氟[18F]贝他嗪一类创新核药专利转让协议及产学研项目合作协议

Core Viewpoint - The announcement highlights a significant collaboration between Yuanzi Gaoke Co., Ltd. and Beijing Normal University, focusing on the development and commercialization of a new drug, Fluorine-18 Betazide, aimed at early diagnosis of Alzheimer's disease [1] Group 1: Collaboration and Agreements - Yuanzi Gaoke signed a patent transfer agreement and a collaborative research agreement with Beijing Normal University on December 10, 2025 [1] - The collaboration is a culmination of previous efforts and marks a critical starting point for transforming scientific research into national productive forces [1] Group 2: Product Development - Fluorine-18 Betazide is a new drug with complete independent intellectual property rights, developed by a team led by Professor Cui Mengchao from Beijing Normal University [1] - The drug has shown significant improvements in clinical applications, particularly in reducing non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Group 3: Industry Context - The nuclear medicine industry is currently experiencing a golden development period, positioning Yuanzi Gaoke as a core player in the field due to its deep industry experience and distinctive characteristics [1] - The partnership aims to accelerate the clinical transformation of core results and build a talent cultivation pathway, contributing to the high-quality development of China's nuclear medicine sector [1]